相似文献
1
Antiarrhythmic drugs, patients, and the pharmaceutical industry: value for patients, physicians, pharmacists or shareholders?
Neth Heart J. 2007;15(4):127-8. doi: 10.1007/BF03085967.
2
Opinions of pharmacy, medicine, and pharmaceutical industry leaders about hypothetical therapeutic-interchange legislation.
Am J Hosp Pharm. 1988 Mar;45(3):570-7.
3
Initial experience with antiarrhythmic medication monitoring by clinical pharmacists in an outpatient setting: a retrospective review.
Clin Ther. 2009 Jun;31(6):1209-18. doi: 10.1016/j.clinthera.2009.06.014.
4
The devil is in the details: the pharmaceutical industry's use of gifts to physicians as marketing strategy.
J Surg Res. 2007 Jun 1;140(1):1-5. doi: 10.1016/j.jss.2006.10.010.
5
Pharmacist-industry relationships.
Int J Pharm Pract. 2017 Dec;25(6):401-410. doi: 10.1111/ijpp.12333. Epub 2017 Jan 18.
6
Evaluation of first year student pharmacists' perceptions of the pharmaceutical industry.
Curr Pharm Teach Learn. 2018 May;10(5):637-642. doi: 10.1016/j.cptl.2018.01.005. Epub 2018 Feb 16.
7
[Benefits and usability of a pharmaceutical record in medical practice. A survey of hospital doctors and pharmacists (MATRIX study)].
Rev Epidemiol Sante Publique. 2016 Sep;64(4):229-36. doi: 10.1016/j.respe.2016.05.001. Epub 2016 Aug 31.
8
Perceptions and Attitudes of Egyptian Health Professionals and Policy-Makers towards Pharmaceutical Sales Representatives and Other Promotional Activities.
PLoS One. 2015 Oct 16;10(10):e0140457. doi: 10.1371/journal.pone.0140457. eCollection 2015.
9
[Sustainable drug prescription: shared perspectives between physicians and pharmacists].
Rev Med Suisse. 2019 May 8;15(650):942-946.
10
Differences in prescribing between GPs: impact of the cooperation with pharmacists and impact of visits from pharmaceutical industry representatives.
Fam Pract. 2005 Dec;22(6):624-30. doi: 10.1093/fampra/cmi074. Epub 2005 Jul 29.
引用本文的文献
1
Comparison of Oral Procainamide and Mexiletine Treatment of Recurrent and Refractory Ventricular Tachyarrhythmias.
J Clin Med. 2024 Oct 13;13(20):6099. doi: 10.3390/jcm13206099.
2
Effectiveness and safety of mexiletine in patients at risk for (recurrent) ventricular arrhythmias: a systematic review.
Europace. 2022 Nov 22;24(11):1809-1823. doi: 10.1093/europace/euac087.
本文引用的文献
1
Electrical storms in Brugada syndrome successfully treated with isoproterenol infusion and quinidine orally.
Neth Heart J. 2007;15(4):151-5. doi: 10.1007/BF03085972.
2
Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator.
Circulation. 2004 Dec 14;110(24):3646-54. doi: 10.1161/01.CIR.0000149240.98971.A8. Epub 2004 Nov 8.
3
Efficacy of quinidine in high-risk patients with Brugada syndrome.
Circulation. 2004 Sep 28;110(13):1731-7. doi: 10.1161/01.CIR.0000143159.30585.90. Epub 2004 Sep 20.
4
The circadian pattern of the development of ventricular fibrillation in patients with Brugada syndrome.
Eur Heart J. 1999 Mar;20(6):465-70. doi: 10.1053/euhj.1998.1332.
5
6
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
N Engl J Med. 1989 Aug 10;321(6):406-12. doi: 10.1056/NEJM198908103210629.
Zotero 插件